A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring

Background

The occurrence of pulmonary adenocarcinoma coexisting with atypical carcinoid tumors is a rare phenomenon. The presence of

Case Description

We report an extremely rare case of

Conclusions

This is the first reported case of coexisting pulmonary adenocarcinoma and atypical carcinoid tumor with an

Informations de copyright

2024 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-352/coif). R.A.R. and T.H. serve as unpaid editorial board members of Translational Lung Cancer Research from January 2024 to December 2025. J.S. is from Dagong Law Firm. E.M.U. received grants from Merck and AstraZeneca; honoraria from Janssen, Amgen, AstraZeneca, Novartis; support for attending meetings and travel from AstraZeneca and Roche; payment for participation in Advisory Board from Roche, Takeda, Pfizer, AstraZeneca. E.S.R. received grants from Sanofi and Takeda; honoraria from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Roche, Takeda; payment for participation in Advisory Board from Roche and Takeda. P.C. has received research funding from AstraZeneca, Amgen, Boehringer Ingelheim, Merck, Novartis, Roche, and Takeda, speaker’s honoraria from AstraZeneca, Gilead, Janssen, Novartis, Roche, Pfizer, Thermo Fisher, Takeda, support for attending meetings from AstraZeneca, Eli Lilly, Daiichi Sankyo, Janssen, Gilead, Novartis, Pfizer, Takeda, and personal fees for participating to advisory boards from AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda and Roche, all outside the submitted work. R.A.R. has consulting agreements with several companies (TerSera Therapeutics, ITM Radiopharma, Regeneron, Advanced Accelerator Applications, Novartis, Ipsen, Amgen, Astra-Zeneca, Curium, Exelexis, EMD Serono) that manufacture products to treat neuroendocrine tumors and lung cancers, all outside the submitted work. R.A.R. is a Board of Directors member of the North American Neuroendocrine Tumor Society. The other authors have no conflicts of interest to declare.